

RAYMED LABS LIMITED

CIN: L24111UP1992PLC014240

Reg. off.-103 Emperor 1, Supertech Emerald Court, Sector 93A Noida,
UP – 201304, Website- www.raymedlab.com

E-mail- raymedlabs@rediffmail.com, Phone no. - 0120-2426900, 9412700300

Date:13/02/2019

The Head- Listing Compliance
BSE Limited
PhirozeJeejeebhoyTowers
Dalal Street
Mumbai-400001

Scrip Code: 531207

Sub: Outcome of Board Meeting pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir(s),

We would like to inform that the Board of Directors in their meeting held today, i.e. Wednesday, 13th day of February, 2019 (commenced at 05:00 P.M. and concluded at 05:30 P.M.), has inter alia approved and passed the following resolutions:

1. Considered and Approved Unaudited Standalone Financial Results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended 31st December, 2018. **(Copy Enclosed)**
2. The Board considered and took on record, the Limited Review Report on Financial Results for the quarter ended 31st December, 2018 as placed by the Statutory Auditor of the Company. **(Copy Enclosed)**
3. The Board took note of Statement of Investor Complaints/Grievances given under Regulation 13(3) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 for the quarter ended 31st December, 2018.

Kindly take the above information on your records.

Thanking you,

For Raymed Labs Limited

(Nisha Goyal)
Director
DIN: 02710946

Raymed Labs Limited
Regd. Office: 103 Emperor 1, Supertech Emerald Court, Sector 93A, Noida - 201304,
Uttar Pradesh, CIN: L24111UP1992PLC014240
E-Mail: raymedlabs@rediffmail.com, Website: www.raymedlab.com,
Tel: 0120-2426900, 9412700300

Statement of Standalone Unaudited Financial Results for the Quarter ended December 31, 2018

Particulars	Amt. (In Lakhs)					
	Quarter Ended			Nine Months Ended		Year Ended
	31-12-2018	30-09-2018	31-12-17	31-12-18	31-12-17	31-03-18
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I. Revenue from Operations	-	-	-	-	-	-
II. Other Income	0.33	0.30	0.3	0.93	0.90	1.20
III. Total Income (I +II)	0.33	0.30	0.3	0.93	0.90	1.20
IV. Expenses						
Cost of Material Consumed	-	-	-	-	-	-
Purchases of Stock-in-trade	-	-	-	-	-	-
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	-	-	-	-	-	-
Employee Benefits Expenses	0.30	0.22	0.23	0.75	0.84	1.06
Finance Costs	-	-	-	-	0.00	0.00
Depreciation and amortisation expenses	0.16	0.16	0.17	0.48	0.51	0.68
Other Expenses	0.46	0.23	0.20	1.16	1.46	2.26
Total Expenses (IV)	0.92	0.61	0.60	2.39	2.81	4.00
V. Profit/(Loss) before exceptional items and tax (III- IV)	(0.59)	(0.31)	(0.30)	(1.46)	(1.91)	(2.80)
VI. Exceptional items	-	-	-	2.95	2.88	2.88
VII. Profit/(Loss) before tax (V-VI)	(0.59)	(0.31)	(0.30)	(4.41)	(4.79)	(5.68)
VIII. Tax Expense						
(1) Current tax	-	-	-	-	-	-
(2) Deferred tax	-	-	-	-	-	-
(3) Previous Year Tax	-	-	-	-	-	-
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	(0.59)	(0.31)	(0.30)	(4.41)	(4.79)	(5.68)
X. Profit/(Loss) from discontinued operations	-	-	-	-	-	-
XI. Tax expense of discontinued operations	-	-	-	-	-	-
XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-	-
XIII. Profit/(Loss) for the period (IX+XII)	(0.59)	(0.31)	(0.30)	(4.41)	(4.79)	(5.68)
XIV. Other Comprehensive Income						
(A) (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
(B) (i) Items that will be classified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV. Total Comprehensive Income for the period (XIII+XIV)	(0.59)	(0.32)	(0.30)	(4.41)	(4.79)	(5.68)
(Comprising Profit (Loss) and Other Comprehensive Income for the Period)						
XVI. Earnings per equity share (for continuing operation):						
(1) Basic	-0.014	-0.007	-0.007	-0.103	-0.112	-0.133
(2) Diluted	-0.014	-0.007	-0.007	-0.103	-0.112	-0.133
XVII. Earnings per equity share (for discontinued operation):						
(1) Basic	-	-	-	-	-	-
(2) Diluted	-	-	-	-	-	-
XVIII. Earnings per equity share (for discontinued & continuing operations)						
(1) Basic	-0.014	-0.007	-0.007	-0.103	-0.112	-0.133
(2) Diluted	-0.014	-0.007	-0.007	-0.103	-0.112	-0.133

Notes:

- The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 13th February 2019. The Statutory Auditors have carried out their limited review of the above results.
- The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The IND AS compliant corresponding figures for the period as reported above have not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification
- As the Company's business activity falls within a single segment, therefore "Segment Reporting" are not applicable.

For Raymed Labs Limited

Nisha Goyal
Director
DIN : 02710946

Date: 13.02.2019
Place : Noida



A. Kay Mehra & Co.

CHARTERED ACCOUNTANTS

2470, Hudson Line, G.T.B. Nagar, Delhi-110009

Tel. No. : 011-42461274, 9891295255

E-mail : akmca1969@gmail.com Website : www.akmca.in

Limited Review Report

To

The Board of Directors

Raymed Labs Limited

103 Emperor 1, Supertech Emerald Court,

Sector 93A, Noida- 201304

We have reviewed the accompanying statement of unaudited financial results ("The Statement") of Raymed Labs Limited ("The Company") for the quarter and nine months ended on December 31, 2018, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A. Kay Mehra & Co.
Chartered Accountants
(F.R.N. 050004C)



Deepak Suneja

CA Deepak Suneja
Partner

(Membership No. 501957)

Place: New Delhi

Date: February 13, 2019

HEAD OFFICE : 120/128, LAJPAT NAGAR, KANPUR-208 005, PH. No. : 0512-2240909, 9956358976

BRANCH OFFICES : C-32, SECTOR-14, NOIDA-201301